A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity

The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV vaccine trials designed to generate antibody responses fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattacini, Laura, Mize, Gregory J., Graham, Jessica B., Fluharty, Tayler R., Graham, Tisha M., Lingnau, Karen, Wizel, Benjamin, Perdiguero, Beatriz, Esteban, Mariano, Pantaleo, Giuseppe, Shen, Mingchao, Spies, Gregory A., McElrath, M. Juliana, Lund, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405041/
https://www.ncbi.nlm.nih.gov/pubmed/22848738
http://dx.doi.org/10.1371/journal.pone.0042163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405041/
https://www.ncbi.nlm.nih.gov/pubmed/22848738
http://dx.doi.org/10.1371/journal.pone.0042163

Ejemplares similares